secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001104659-21-133381
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics appoints Christopher Posner as President and CEO; Derek Chalmers transitions to Senior Advisor
--------------------------------------------------------------------------------

- Christopher Posner, former LEO Pharma US CEO and current Cara board member, becomes President and CEO effective Nov 9.
- Derek Chalmers steps down as President, CEO, and director effective Nov 8; will serve as Senior Advisor through June 2022.
- Posner receives $680K base salary, $400K signing bonus, equity awards (566K option shares, 142K RSUs).
- Chalmers receives 12 months base salary, COBRA coverage, 2021 target bonus, and extended equity vesting.
- KORSUVA injection (FDA-approved for pruritus in dialysis) to launch; oral KORSUVA for atopic dermatitis advanced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/0001104659-21-133381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465921133381/tm2131541d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-133381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer